Adagene (ADAG) vs Veraxa Biotech (VRXA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Adagene (ADAG) has outperformed Veraxa Biotech (VRXA) over the past year, gaining 42.2% versus a loss of 89.6%. Adagene is the larger company by market cap ($184.6 million vs $171.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADAG | VRXA |
|---|---|---|
| Share price | $2.75 | $1.21 |
| Market cap | $184.64M | $171.10M |
| 1-day change | -1.08% | +11.01% |
| YTD return | +47.09% | -89.78% |
| 1-year return | +42.20% | -89.58% |
| 5-year return | -76.24% | — |
| EPS (TTM) | $-0.37 | $-0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.85 | $27.36 |
| 52-week low | $1.30 | $1.04 |
| Distance from 52-week high | -43.30% | -95.58% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +260.36% | — |
| Average volume | 244.76K | 267.20K |
| Shares outstanding | 67.14M | 141.41M |
| Employees | 128 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADAG has outperformed VRXA by 131.8 percentage points over the past year.
About Adagene
ADAG stock →Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Veraxa Biotech
VRXA stock →VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.
Health Care · Biotechnology: Pharmaceutical Preparations
ADAG vs VRXA FAQ
Which is bigger, Adagene or Veraxa Biotech?
Adagene (ADAG) is larger, with a market capitalization of $184.64M compared with $171.10M for Veraxa Biotech (VRXA).
Which stock has performed better over the past year, ADAG or VRXA?
ADAG returned +42.20% over the past 12 months, compared with -89.58% for VRXA (price return, excluding dividends). Past performance does not predict future results.
Are Adagene and Veraxa Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.